GB Sciences, Inc. (OTCQB:GBLX) has partnered with Purisys, LLC to supply ultra-high purity cannabinoids for its cannabinoid-containing optimized therapeutic mixtures (OTM). This strategic alliance aims to enhance the standardization and quality of GB Sciences' pharmaceutical products, particularly essential for preclinical and clinical trials. GB Sciences holds a robust intellectual property portfolio with 5 US and 3 international patents, alongside multiple pending applications targeting various medical conditions. The lead program focuses on developing a therapeutic for Parkinson's disease.
GB Sciences (OTCQB:GBLX) filed a provisional patent for its innovative drug discovery platform, integrating data analytics and machine learning to identify effective plant-derived therapeutics. This platform aims to expedite the development of novel combination drugs, enhancing research efficiency and addressing unmet medical needs. GBS has previously secured three US patents targeting conditions like Parkinson's and pain, with additional patents pending both domestically and internationally. The company seeks to leverage its extensive intellectual property to create optimized therapeutic mixtures.
GB Sciences has collaborated with the Universidad de Sevilla to publish a paper on terpene-containing nanoparticles for pain treatment, featured in Industrial Crops and Products. This study outlines a novel method for developing time-released drug delivery systems for terpenes, which are highly volatile and lipophilic molecules. The patented technology aims to enhance pain relief, addressing the significant health burden of chronic pain in the U.S., estimated between $560 and $650 billion. Currently, animal trials are underway, paving the way for future FDA clinical trials.
GB Sciences, Inc. (OTCQB:GBLX) has filed a provisional patent for its proprietary cannabinoid containing complex mixtures (CCCM™) aimed at treating chronic inflammation, a condition costing over $130 billion annually. This development follows a two-year study conducted at Michigan State University, highlighting CCCM™'s potential in treating chronic neuroinflammation linked to disorders like HIV-Associated Neurocognitive Disorder, Parkinson's, and Alzheimer's. The company is expanding its intellectual property portfolio, with multiple applications pending both in the U.S. and internationally.
GB Sciences, Inc. (OTCQB:GBLX) has filed a provisional patent for its proprietary cannabinoid containing complex mixtures (CCCM™) aimed at treating Cytokine Storm Syndromes and acute respiratory distress syndrome (ARDS) in COVID-19 patients. The CCCM™ targets specific cytokines to mitigate inflammation while preserving immune responses essential for fighting infections. With a growing demand for innovative anti-inflammatory therapies amid the COVID-19 pandemic, these CCCM™ represent a significant advancement. GBS currently holds four issued patents and has multiple applications pending worldwide.